TEE
AMRX icon

Tibra Equities Europe’s Amneal Pharmaceuticals AMRX Stock Holding History

Tibra Equities Europe’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,100
Closed -$710K – 241
2019
Q1 		$710K Buy
+50,100
New +$662K 0.07% 216

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Tibra Equities Europe's AMRX Position: Q2 2019 in Review

Tibra Equities Europe sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 50,100 shares — an estimated $710K sold.

Tibra Equities Europe first reported a position in AMRX in Q1 2019 and held it in 1 quarter. The position peaked at $710K in Q1 2019. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

  • Tibra Equities Europe reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 50,100 Amneal Pharmaceuticals shares in Q2 2019, an estimated $710K.
  • Tibra Equities Europe first reported a position in Amneal Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Amneal Pharmaceuticals position peaked at $710K in Q1 2019.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.